Country | Number of patients in the registry | Rate per 1 million of population | Percentage of patients diagnosed before 18 y.o. | Median (mean) follow-up period, years | Total person years | Percentage of patients with identified relative monthly Ig dose | Mean (SD) monthly Ig dose, mg/kg |
---|---|---|---|---|---|---|---|
Austria | 5 | 0.6 | 80.0% | 9.0 (10.6) | 53 | 80% | 450 (327) |
Belarus | 2 | 0.2 | 100% | 3.0 (3.0) | 6 | N.A. | N.A. |
Belgium | 21 | 1.9 | 71.4% | 6.0 (7.7) | 162 | 61.9% | 431 (110) |
Czech Republic | 90 | 8.6 | 30.0% | 11.0 (12.1) | 1093 | 80% | 266 (146) |
Egypt | 4 | 0.5 | 100% | 12.0 (10.3) | 41 | 75% | 300 (265) |
Estonia | 6 | 4.5 | 16.7% | 6.5 (5.5) | 33 | 100% | 361 (70) |
France | 319 | 5.1 | 18.8% | 6.0 (10.5) | 3334 | 65.8% | 538 (178) |
Georgia | 1 | 0.2 | 100% | 5.0 (5.0) | 5 | 100% | 369 (−) |
Germany | 475 | 5.8 | 34.5% | 7.0 (9.2) | 4377 | 71.6% | 385 (184) |
Greece | 34 | 3.1 | 76.5% | 6.0 (9.3) | 317 | 67.6% | 544 (182) |
Ireland | 20 | 4.4 | 15.0% | 15.5 (15.1) | 302 | 50% | 510 (68) |
Italy | 397 | 6.7 | 27.7% | 7.0 (8.7) | 3470 | 56.4% | 405 (218) |
Lithuania | 4 | 1.3 | 0.0% | 4.0 (6.5) | 26 | 75% | 380 (99) |
Netherlands | 183 | 11.0 | 38.3% | 8.0 (9.9) | 1803 | 56.3% | 508 (214) |
Poland | 39 | 1.0 | 100% | 5.0 (5.6) | 218 | 100% | 430 (142) |
Russia | 20 | 0.1 | 100.0% | 6.0 (5.5) | 110 | 90% | 442 (146) |
Serbia | 11 | 1.5 | 81.8% | 4.0 (5.5) | 60 | 90.9% | 400 (0) |
Slovakia | 13 | 2.4 | 84.6% | 3.0 (5.5) | 71 | 100% | 392 (156) |
Spain | 258 | 5.5 | 24.4% | 1.0 (3.4) | 884 | 12.8% | 412 (175) |
Sweden | 14 | 1.5 | 7.1% | 8.0 (10.0) | 140 | 78.6% | 498 (221) |
Switzerland | 26 | 3.3 | 30.8% | 7.0 (7.6) | 197 | 69.2% | 477 (287) |
Turkey | 75 | 1.0 | 76.0% | 5.0 (5.6) | 420 | 72% | 472 (107) |
U.K. | 683 | 10.9 | 18.9% | 7.0 (10.6) | 7244 | 52.6% | 528 (165) |
Total/ overall | 2700 | 3.9 | 30.5% | 6.0 (9.0) | 24,366 | 58.0% | 454 (196) |